Richard W. Pascoe - 09 Jan 2023 Form 4 Insider Report for KEMPHARM, INC (ZVRA)

Role: Chief Executive Officer, Director
Signature: /s/ Timothy J. Sangiovanni, Attorney-in-Fact for Richard W. Pascoe
Issuer symbol: ZVRA
Transactions as of: 09 Jan 2023
Net transactions value: $0
Form type: 4
Filing time: 11 Jan 2023, 20:46:56 UTC
Previous filing: 05 Jan 2023
Next filing: 13 Jan 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ZVRA	Stock Option (right to buy)	Award	$0	+700,000		$0.000000	700,000	09 Jan 2023	Common Stock	700,000	$4.54	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan (the "Plan"). 25% of the shares will vest on January 6, 2024 and the remaining 75% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant.

Content

Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan (the "Plan"). 25% of the shares will vest on January 6, 2024 and the remaining 75% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant.